Captrust Financial Advisors Exelixis, Inc. Transaction History

Captrust Financial Advisors

$30.9 Billion
Q2 2024

A detailed history of Captrust Financial Advisors transactions in Exelixis, Inc. stock. As of the latest transaction made, Captrust Financial Advisors holds 34,062 shares of EXEL stock, worth $913,883. This represents 0.0% of its overall portfolio holdings.

Number of Shares

34,062

Previous 32,406 5.11%

Holding current value

$913,883

Previous $768,000 0.39%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$20.34 - $23.73 $33,683 - $39,296	1,656 Added 5.11%	34,062 $765,000
Q1 2024 May 15, 2024	SELL	$20.17 - $23.93 $394,182 - $467,663	-19,543 Reduced 37.62%	32,406 $768,000
Q4 2023 Feb 14, 2024	BUY	$19.25 - $24.13 $192,962 - $241,879	10,024 Added 23.91%	51,949 $1.25 Million
Q3 2023 Nov 14, 2023	BUY	$19.04 - $22.74 $438,624 - $523,861	23,037 Added 121.97%	41,925 $916,000
Q2 2023 Aug 14, 2023	BUY	$18.17 - $20.48 $33,705 - $37,990	1,855 Added 10.89%	18,888 $360,000
Q1 2023 May 15, 2023	BUY	$16.3 - $19.41 $55,077 - $65,586	3,379 Added 24.75%	17,033 $330,000
Q4 2022 Feb 15, 2023	SELL	$14.96 - $17.39 $31,595 - $36,727	-2,112 Reduced 13.4%	13,654 $219,000
Q3 2022 Nov 16, 2022	BUY	$15.68 - $22.27 $154,777 - $219,827	9,871 Added 167.45%	15,766 $247,000
Q2 2022 Aug 23, 2022	SELL	$17.44 - $23.16 $8,004 - $10,630	-459 Reduced 7.22%	5,895 $123,000
Q2 2022 Aug 16, 2022	SELL	$17.44 - $23.16 $69,742 - $92,616	-3,999 Reduced 38.63%	6,354 $132,000
Q1 2022 May 16, 2022	SELL	$17.03 - $22.67 $2,520 - $3,355	-148 Reduced 1.41%	10,353 $235,000
Q4 2021 Feb 14, 2022	BUY	$15.84 - $21.88 $17,756 - $24,527	1,121 Added 11.95%	10,501 $192,000
Q3 2021 Nov 16, 2021	SELL	$16.3 - $21.14 $89,046 - $115,487	-5,463 Reduced 36.81%	9,380 $198,000
Q2 2021 Aug 16, 2021	SELL	$17.95 - $25.56 $111,236 - $158,395	-6,197 Reduced 29.45%	14,843 $270,000
Q1 2021 May 17, 2021	BUY	$20.53 - $25.22 $248,228 - $304,935	12,091 Added 135.11%	21,040 $475,000
Q4 2020 Feb 16, 2021	BUY	$18.39 - $24.8 $7,631 - $10,292	415 Added 4.86%	8,949 $180,000
Q3 2020 Nov 17, 2020	BUY	$20.67 - $26.94 $39,066 - $50,916	1,890 Added 28.45%	8,534 $209,000
Q2 2020 Aug 14, 2020	BUY	$16.46 - $27.42 $32,821 - $54,675	1,994 Added 42.88%	6,644 $156,000
Q1 2020 May 15, 2020	BUY	$14.46 - $21.8 $67,239 - $101,370	4,650 New	4,650 $77,000
Q2 2019 Aug 13, 2019	SELL	$18.93 - $24.75 $53,590 - $70,067	-2,831 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$19.6 - $24.76 $55,487 - $70,095	2,831 New	2,831 $67,000
Q4 2018 Feb 13, 2019	SELL	$13.65 - $21.8 $4,095 - $6,540	-300 Closed	0 $0
Q3 2018 Nov 15, 2018	BUY	$15.87 - $22.4 $4,761 - $6,720	300 New	300 $5,000

Others Institutions Holding EXEL

# of Institutions

460

Shares Held

240M

Call Options Held

2.04M

Put Options Held

1.29M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $8.63B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Captrust Financial Advisors with notifications on news.

Account

Captrust Financial Advisors Exelixis, Inc. Transaction History